Showing 11-20 of 346 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Production of SC-islets for distribution | Advanced Regenerative Manufacturing Institute (ARMI) | Thomas Bollenbach | Cures | 01-March-2026 to 30-November-2026 | $471.977,53 |
| Utilizing AI to Establish an Inception Cohort of Persons Living with Type 1 Diabetes Mellitus to Study Trajectories of Glycemic Variability and Related Risk Factors and Their Influence on Subsequent Risk of Cardiovascular Disease | Northwestern University | Sara Hassani | Improving Lives | 01-April-2026 to 31-March-2029 | $1.014.920,00 |
| The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation | Virginia Commonwealth University | Derek Sant’Angelo | Cures | 01-September-2025 to 31-August-2026 | $382.996,65 |
| Alternative Splicing as a Trigger for Initiation and Progression of Islet Autoimmunity | Rector & Visitors of the University of Virginia | Stephen Rich | Cures | 01-February-2026 to 31-January-2029 | $880.914,00 |
| Do Islet Somatic Mutations Contribute to T1D Age at Onset? | Beckman Research Institute of the City of Hope | Melanie Shapiro | Cures | 01-March-2026 to 28-February-2027 | $100.000,00 |
| Regenerable Reagentless Sensors for Continuous Monitoring of Insulin | Northwestern University | Shana Kelley | Improving Lives | 01-March-2026 to 29-February-2028 | $348.937,89 |
| NKG2D Signaling as a Critical Modulator of Autoreactive CD8⁺ T Cell Differentiation and β Cell Destruction in Type 1 Diabetes | University of Kansas Medical Center Research Institute, Inc. | Ambika Dudhate | Cures | 01-March-2026 to 28-February-2029 | $274.010,00 |
| Understanding Early Histopathological Changes in the Pancreas of those at Risk for Type 1 Diabetes Development | University of Florida | Alexandra Rippa | Cures | 01-March-2026 to 28-February-2029 | $237.690,00 |
| IL-37 expressing Treg cells to improve T1D therapeutic strategy | University of California, San Diego | Mayumi Fujita | Cures | 01-September-2025 to 28-February-2026 | $161.904,81 |
| Harnessing Neonatal Regulatory T Cells for Precision Immunotherapy in Type 1 Diabetes | Boston Children’s Hospital | Ayano Kohlgruber | Cures | 01-March-2026 to 28-February-2031 | $998.713,47 |